News
Press Releases
-
Mar 04, 2021
Pulmonary Fibrosis Foundation Launches Industry Consortium To Identify Biomarkers In Pulmonary Fibrosis
The Pulmonary Fibrosis Foundation (PFF) today announced a new collaboration that could speed up the development of targeted treatments for individuals with idiopathic pulmonary fibrosis (IPF), a devastating and progressive lung disease.Read More Pulmonary Fibrosis Foundation Launches Industry Consortium To Identify Biomarkers In Pulmonary Fibrosis
Media Mentions
-
May 06, 2020
Partnership to Identify IPF Biomarkers Aimed at Enabling Optimal Patient Treatment
The Pulmonary Fibrosis Foundation (PFF) has co-founded an industry-wide effort to identify new blood biomarkers specific to IPF with the goal of predicting which patients would benefit most from certain medications.
Read the ArticleSource: Responsum for PF -
Mar 09, 2020
Pulmonary Fibrosis Foundation Launches Industry Consortium to Identify Biomarkers in Pulmonary Fibrosis
The Pulmonary Fibrosis Foundation (PFF) today announced a new collaboration that could speed up the development of targeted treatments for individuals with idiopathic pulmonary fibrosis (IPF), a devastating and progressive lung disease.
Read the ArticleSource: Clinical Labs Products -
Mar 04, 2020
Pulmonary Fibrosis Foundation, Celgene Form Biomarker Consortium
The Pulmonary Fibrosis Foundation (PFF) has partnered with Bristol-Myers Squibb subsidiary Celgene to launch a research consortium to identify biomarkers of pulmonary fibrosis that can guide therapy.
Read the ArticleSource: GenomeWeb